The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
National Comprehensive Cancer Network.NCCN testicular cancer practice guidelines. The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM].Rockledge, PA: National Comprehensive Cancer Network; 2003.
2.
KattanJ., MahjoubiM., DrozJ.P.High failure rate of carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours. Eur J Cancer.1993; 29A (11): 1504–9.
3.
BajorinD.F., SarosdyM.F., PfisterD.G.Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol.1993; 11(4): 598–606.
4.
TjulandinS.A., GarinA.M., MescheryakovA.A.Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors. Ann Oncol.1993; 4(8): 663–7.
5.
BoslG.J., BajorinD.F.Etoposide plus carboplatin or cisplatin in good-risk patients with germ cell tumors: A randomized comparison. Semin Oncol.1994; 21(5 suppl 12):61–4.
6.
PeckhamM.J., HorwichA., BlackmoreC.Etoposide and cisplatin with or without bleomycin as first-line chemotherapy for patients with smallvolume metastases of testicular nonseminoma. Cancer Treat Rep.1985; 69(5): 483–8.
7.
HainsworthJ.D., WilliamsS.D., EinhornL.H.Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: Results of a Southeastern Cancer Study Group trial. J Clin Oncol.1985; 3(5): 666–71.
8.
BoslG.J., GellerN.L., BajorinD.A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol.1988; 6(8): 1231–8.
9.
BajorinD.F., GellerN.L., WeisenS.F.Two-drug therapy in patients with metastatic germ cell tumors. Cancer.1991; 67(1): 28–32.
10.
MotzerR.J., SheinfeldJ., MazumdarM.Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol.1995; 13(11): 2700–4.
11.
HorwichA., OliverR.T., WilkinsonP.M.A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. Br J Cancer.2000; 83(12): 1623–9.
12.
de WitR., StoterG., KayeS.B.Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol.1997; 15(5): 1837–43.
13.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–9.
14.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm.1999; 56: 729–64.
15.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. The Complete Library of NCCN Oncology Practice Guidelines [CD-ROM].Rockledge, PA: National Comprehensive Cancer Network; 2003.
16.
GrallaR.J., OsobaD., KrisM.G.Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17(9): 2971–94.
17.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50: 147–58.
18.
KintzelP.E.Anticancer drug-induced kidney disorders: Incidence, prevention and management. Drug Safety.2001; 24: 19–38.
OzerH., ArmitageJ.O., BennettC.L.2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol.2000; 18(20): 3558–85.
LymanG.H., KudererN., GreeneJ.The economics of febrile neutropenia: Implications for the use of colony-stimulating factors. Eur J Cancer.1998; 34(12): 1857–64.
23.
LymanG.H., BalducciL.Update of the economic analyses of the use of colony-stimulating factors. Curr Opin Hematol.1999; 6(3): 145–51.
24.
LymanG.H.A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care. Eur J Cancer.2000; 36(suppl 1): S15–S21.
25.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–9.
26.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–402.
27.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001; 494–504.
28.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
29.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am.1995; 24(4): 969–89.
